Table 4.
Response evaluation of patients after SBRT
| Group without progression | |||||
|---|---|---|---|---|---|
| 1 month n = 96 |
3 months n = 96 |
6 months n = 96 |
12 months n = 66 |
> 12 months n = 55 |
|
| LI-RADS treatment response | |||||
| LR-TR nonviable | 10 (10) | 35 (46) | 50 (52) | 42 (64) | 38 (69) |
| LR-TR equivocal | 86 (90) | 61 (64) | 46 (48) | 24 (36) | 17 (31) |
| LR-TR viable | 0 | 0 | 0 | 0 | 0 |
| Modified LI-RADS treatment response | |||||
| LR-TR nonviable | 39 (41) | 71 (74) | 85 (89) | 63 (95) | 54 (98) |
| LR-TR equivocal | 57 (59) | 25 (26) | 11 (11) | 3 (5) | 1 (2) |
| LR-TR viable | 0 | 0 | 0 | 0 | 0 |
| m-RECIST | |||||
| Complete response | 10 (10) | 35 (36) | 50 (52) | 42 (64) | 38 (69) |
| Partial response | 27 (28) | 37 (39) | 34 (35) | 20 (30) | 15 (27) |
| Stable disease | 49 (51) | 22 (23) | 12 (13) | 4 (6) | 2 (4) |
| Progressive disease | 10 (10) | 2 (2) | 0 | 0 | 0 |
SBRT stereotactic body radiation therapy, LI-RADS Liver Reporting and Data System; m-RECIST Modified Response Evaluation Criteria in Solid Tumors